Calvert Holdings

Calvert Holdings provides vision, resources, and business leadership for all of the companies it develops and acquires. Life sciences are a core competency, but not all our business endeavors are within that field. Click the links to explore our companies, or contact us for more information.
Contact Calvert Holdings

Other Calvert Companies

Portfolio

Active Investments

Calvert T1, LLC is a virtual company owned by Calvert Research that has licensed patent-protected compounds and enabling technology from Tulane University for the potential treatment of a variety of ocular diseases.  The lead drug candidate (T1-1081) is undergoing preclinical evaluation as a potentially more effective treatment for the wet form of Age-related Macular Degeneration (AMD), which is a significant cause of vision loss and blindness in people over age 50 affecting millions worldwide.  T1-1081 was specifically designed to impact multiple points in the pathogenesis of wet AMD by preventing inflammation, blocking new blood vessel growth and simultaneously targeting and destroying newly formed blood vessels in the back of the eye.  T1-1081 also has the potential to treat other serious ocular diseases such as diabetic retinopathy or the dry form of AMD.

Drug Delivery Nanotechnology (sponsored research at Auburn University): Calvert is co-developing a targetable lipid drug delivery nanotechnology to deliver siRNA or small molecules for cancer. Proof-of-efficacy studies will be conducted at Calvert Labs once this research concludes.

Exited Investments

CureDM, Inc. (a technology originating from the University of Pennsylvania) is developing PancreateTM, a patented islet neogenesis drug candidate for the potential treatment of Type I and 2 diabetic patients.  In preclinical studies, PancreateTM has been shown to stimulate the growth of new insulin producing islets in the pancreas, resulting in restoration of normal metabolic function and glucose control.  Calvert Research is a significant investor in CureDM and has provided valuable expertise to the company in a number of areas including the design and execution of IND-enabling animal studies that were conducted at Calvert Laboratories, project management services and corporate identity development.

In April, 2010 CureDM signed an exclusive worldwide license agreement with Sanofi-Aventis for further development and commercialization of PancreateTM, which is expected to enter human clinical trials in late 2010.  Under the terms of the license agreement, CureDM will receive an upfront cash payment and is eligible to receive success based development, regulatory and sales performance milestone payments totaling $335 million, in addition to royalties on worldwide product sales.  As a major shareholder in CureDM, Calvert Research is entitled to receive significant cash payments from this license agreement as PancreateTM advances through further clinical development and into commercialization.

AcSentient, Inc. focused on ophthalmic and dermatology products. Calvert provided seed capital to establish this development company. The rights to compounds accumulated by AcSentient were subsequently transferred to Ista Pharmaceuticals, Inc. (ISTA – Nasdaq) in May, 2002. Calvert remains a shareholder of ISTA as a result of this transaction.

Pinnacle Pharmaceuticals (a University of Virginia technology) developed a novel compound effective against multi-drug-resistant bacterial strains. Proof-of-efficacy studies were conducted at Calvert Labs for equity, and the company was subsequently acquired by New River Pharmaceuticals.